NASDAQ:PDLI

PDL BioPharma (PDLI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.47
$2.47
50-Day Range
$2.47
$2.47
52-Week Range
$2.09
$3.86
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PDLI stock logo

About PDL BioPharma Stock (NASDAQ:PDLI)

PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

PDLI Stock News Headlines

GT Biopharma Inc GTBP
Health Winners & Losers: Maxygen
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
PDLI Historical Data
ABVC - ABVC BioPharma, Inc.
RDHL - RedHill Biopharma Ltd.
LABP
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Steris (STE)
See More Headlines
Receive PDLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDL BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2020
Today
4/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PDLI
CUSIP
69329Y10
Employees
109
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dominique P. Monnet (Age 59)
    CEO, Pres & Director
    Comp: $1.2M
  • Mr. Edward A. Imbrogno CPA (Age 55)
    VP, CFO & Chief Accounting Officer
    Comp: $564.14k
  • Mr. Christopher L. Stone (Age 56)
    VP, Gen. Counsel & Sec.
    Comp: $1.15M
  • Mr. Nathan Kryszak
    Deputy Gen. Counsel & Assistant Sec.

PDLI Stock Analysis - Frequently Asked Questions

How were PDL BioPharma's earnings last quarter?

PDL BioPharma, Inc. (NASDAQ:PDLI) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by $0.53. The biotechnology company earned $5.21 million during the quarter.

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Bausch Health Companies (BHC) and Cara Therapeutics (CARA).

This page (NASDAQ:PDLI) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners